Helius Medical Technologies, Inc. (HSDT)
NASDAQ: HSDT · Real-Time Price · USD
5.98
+0.05 (0.84%)
Aug 11, 2025, 10:59 AM - Market open
Paramount Global Revenue
Helius Medical Technologies had revenue of $49.00K in the quarter ending March 31, 2025, a decrease of -63.70%. This brings the company's revenue in the last twelve months to $434.00K, down -35.03% year-over-year. In the year 2024, Helius Medical Technologies had annual revenue of $520.00K, down -19.25%.
Revenue (ttm)
$434.00K
Revenue Growth
-35.03%
P/S Ratio
9.30
Revenue / Employee
$20,667
Employees
21
Market Cap
4.07M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 520.00K | -124.00K | -19.25% |
Dec 31, 2023 | 644.00K | -143.00K | -18.17% |
Dec 31, 2022 | 787.00K | 265.00K | 50.77% |
Dec 31, 2021 | 522.00K | -139.00K | -21.03% |
Dec 31, 2020 | 661.00K | -835.00K | -55.82% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
HSDT News
- 21 days ago - Helius Announces Positive Outcome of the Portable Neuromodulation Stimulator PoNS® Stroke Registrational Program and Upcoming Submission to FDA Under Breakthrough Designation - GlobeNewsWire
- 4 weeks ago - Helius Medical Technologies, Inc. Compliant with Nasdaq's Continued Listing Requirements - GlobeNewsWire
- 4 weeks ago - Helius Medical Technologies, Sunrun And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
- 6 weeks ago - Helius Medical Technologies Announces Reverse Stock Split - GlobeNewsWire
- 2 months ago - Helius Medical Technologies, Inc. Announces Claim Authorization by CignaHealth, for its Portable Neuromodulation Stimulator (PoNS®) Device - GlobeNewsWire
- 2 months ago - Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting - GlobeNewsWire
- 2 months ago - Helius Medical Technologies, Inc. Announces Authorized Claim for Payment by Major Healthcare Payer for its Portable Neuromodulation Stimulator (PoNS®) Device - GlobeNewsWire
- 2 months ago - Helius Medical Technologies Announces Pricing of $9.1 Million Public Offering - GlobeNewsWire